Accessibility Menu
Coherus Oncology Stock Quote

Coherus Oncology (NASDAQ: CHRS)

$1.68
(-3.4%)
-0.06
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$1.68
Daily Change
(-3.4%) $0.06
Day's Range
$1.64 - $1.74
Previous Close
$1.68
Open
$1.74
Beta
1.56
Volume
844,034
Average Volume
1,328,378
Market Cap
195.3M
Market Cap / Employee
$1.68M
52wk Range
$0.66 - $2.43
Revenue
-
Gross Margin
0.54%
Dividend Yield
N/A
EPS
-$1.38
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Coherus Oncology Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CHRS+95.03%-90.45%-37.48%-87%
S&P+14.5%+93.32%+14.09%+230%

Coherus Oncology Company Info

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$10.25M-84.2%
Gross Profit$5.84M-83.5%
Gross Margin56.98%2.5%
Market Cap$84.78M-57.3%
Market Cap / Employee$0.37M0.0%
Employees228-25.5%
Net Income-$44.86M-247.2%
EBITDA-$44.47M-130.2%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$216.89M36.2%
Accounts Receivable$5.11M-97.1%
Inventory4.5-92.7%

Liabilities

Q2 2025YOY Change
Long Term Debt$52.37M-82.2%
Short Term Debt$1.76M-57.4%

Ratios

Q2 2025YOY Change
Return On Assets-27.59%-22.5%
Return On Invested Capital-37.81%-2.6%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$46.63M-178.1%
Operating Free Cash Flow-$46.63M-178.1%

Valuation

MetricQ4 2024YoY Change
Price to Earnings7.91-
Price to Book-1.36-1.81-0.71-0.46-80.74%
Price to Sales0.390.600.470.59-7.77%
Price to Tangible Book Value-0.84-1.12-0.50-0.36-74.63%
Price to Free Cash Flow TTM186.99-
Enterprise Value to EBITDA-66.48-9.61-7.002.22-112.69%
Free Cash Flow Yield0.5%-
Return on Equity-860.6%-
Total Debt$299.48M$298.65M$299.50M$54.13M-81.86%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.